The eMurmur® ID, a new first-in-class artificial intelligence-based solution that enables healthcare professionals to detect and classify heart murmurs with expert-level accuracy on a personal mobile device, has received clearance from the US Food and Drug Administration.

eMurmur ID is a mobile and cloud solution that operates in conjunction with a third-party electronic stethoscope to identify and classify pathologic and innocent heart murmurs, the absence of a heart murmur, and S1, S2 heart sounds. The solution is comprised of artificial intelligence-based analytics, a mobile app, a Health Insurance Portability and Accountability Act-compliant server, and a web portal that supports the workflows of healthcare providers performing cardiac auscultation.

Related Articles

Derek Exner, MD, MPH, professor and Canada Research Chair in Cardiovascular Clinical Trials at the University of Calgary, Alberta, Canada, commented that, “The evidence for its utility is solid and includes five studies on over 1000 patients, including blinded, multi-center trials. This system has been shown to be accurate, informative, and easy-to-use. It provides healthcare professionals with a potent screening tool and method to confirm their clinical diagnoses, enhancing patient care.”  

Continue Reading

eMurmur is a medical technology company headquartered in Ottawa, Ontario, Canada, that specializes in machine learning for the analysis of data for medical applications and is the leader in automated heart murmur detection technology.


Masucol J. FDA grants clearance for eMurmur ID, heart murmur detection solution on a personal mobile device [published online May 7, 2019].